Author:
Zagouri Flora,Sergentanis Theodoros N.,Chrysikos Dimosthenis,Zografos Constantine G.,Papadimitriou Christos A.,Dimopoulos Meletios-Athanassios,Filipits Martin,Bartsch Rupert
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Endocrinology,Hepatology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference147 articles.
1. Cancer statistics, 2010.;Jemal;CA Cancer J Clin,2010
2. 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.;Burris;J Clin Oncol,1997
3. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.;Cunningham;J Clin Oncol,2009
4. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.;Moore;J Clin Oncol,2007
5. Randomized phase III trial comparing FOLFIRINOX (F: 5FUleucovorin LV, irinotecan I, and oxaliplatin O) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): preplanned interim analysis results of the PRODIGE 4ACCORD 11 trial.;Conroy;ASCO Meeting Abstracts,2010
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献